热门资讯> 正文

Denali Therapeutics在2026年世界研讨会上展示有关酶运输车辆计划的数据

2026-01-30 05:04

Denali治疗(DNLI) 0

Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review
Preliminary data from Phase 1/2 study of DNL126 (ETV:SGSH) for Sanfilippo syndrome type A (MPS IIIA) to be featured in oral presentation
- Phase 1 study design of DNL952 (ETV:GAA) for Pompe disease and supporting preclinical data will appear in poster session

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。